Loading live market data…

Elevance Health Inc.

NYSE:ELV

$386.42499 USD

-$40.37 (-9.46%)

Volume
2.78M
Average Volume
1.73M
Market Capitalization
$83.92B
P/E Ratio
17.17
Dividend Yield
1.78%
Price Target
$444.50
Year High
$436.24
Year Low
$273.71
Day High
Day Low
Payout Ratio
$0.30
Current Ratio
$1.52
Source Headline
Elevance Health, Inc. (ELV) Q2 2026 Earnings Call Transcript

Elevance Health, Inc. (ELV) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-15 15:07:57

ELV Beats Q2 Earnings Estimates on Higher CarelonRx Product Revenues

Elevance Health beats Q2 EPS and revenue estimates, raises 2026 adjusted EPS outlook despite lower earnings, softer membership and higher expenses.

zacks.com - 2026-07-15 14:06:06

Dow Jones Stays Calm While Memory Chips Give Investors Whiplash (Again)

Inflation data gave investors hope on Wednesday morning. Semiconductor stocks took it away by lunchtime.

fool.com - 2026-07-15 12:48:59

Elevance Health Q2 Earnings Call Highlights

Elevance Health NYSE: ELV raised its 2026 adjusted earnings outlook after second-quarter results came in ahead of management's expectations, citing favorable benefit expense performance, disciplined cost management and improving execution across several major business lines.

marketbeat.com - 2026-07-15 11:04:47

Compared to Estimates, Elevance Health (ELV) Q2 Earnings: A Look at Key Metrics

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-07-15 10:31:06

Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates

Elevance Health (ELV) came out with quarterly earnings of $7.45 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $8.84 per share a year ago.

zacks.com - 2026-07-15 08:12:10

Elevance Health Profits Eclipse $1.4 Billion As Costs Ease Somewhat

Elevance Health reported second quarter net income of $1.45 billion as medical costs fell in some health plans, triggering an improved outlook for the rest of the year.

forbes.com - 2026-07-15 07:15:09

Elevance Health Raises Earnings Outlook on Higher Sales

The health insurer raised its earnings outlook after logging a higher benefit-expense ratio and sales number in the second quarter.

wsj.com - 2026-07-15 06:44:00

Elevance raises annual profit forecast on better medical cost management

Elevance Health ​raised its annual profit forecast after beating second-quarter ‌earnings estimates on Wednesday, as it looks to keep medical costs in check.

reuters.com - 2026-07-15 06:19:49

Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported second quarter 2026 results ahead of expectations. "Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio. We are raising our 2026 adjusted EPS guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating ef.

businesswire.com - 2026-07-15 06:00:00

Will Health Benefits Weakness Drag Elevance's Q2 Earnings?

ELV faces Q2 pressure as weaker Health Benefits results and higher benefit expenses may weigh on earnings ahead of its July 15 report.

zacks.com - 2026-07-13 15:11:07

Eyes On Elevance Health, UnitedHealth For Continued Insurer Rebound

This week's Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies' health insurance businesses and that of their rivals are keeping a handle on rising costs.

forbes.com - 2026-07-13 07:05:12

Elevance and UnitedHealth Earnings Are Next Test for Hot Health Insurer Stocks

Elevance reports results July 15, followed by UnitedHealth July 16, and CVS Health on Aug. 5.

barrons.com - 2026-07-13 03:00:00

Elevance Health: Defense For An Undervalued Price

Elevance Health has outperformed the benchmark, rising 28% versus 11%, and I see further upside potential. ELV demonstrates steady top- and bottom-line growth, supporting a premium multiple and reinforcing management confidence. The insurance market's steady growth is a structural tailwind; if ELV maintains market share, it stands to benefit.

seekingalpha.com - 2026-07-11 08:45:00

Is ELV's Capital Allocation Strategy Creating Long-Term Value?

Elevance Health's disciplined capital allocation, strong cash generation and continued investments in Carelon and AI support long-term growth while rewarding shareholders.

zacks.com - 2026-07-10 13:25:23

Curious about Elevance Health (ELV) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

zacks.com - 2026-07-10 10:16:09

3 Cheap Medical Stocks to Buy as US-Iran Tensions Keep Markets on Edge

U.S.-Iran tensions likely to lift demand for defensive plays, with Tenet Healthcare, Elevance Health and Aveanna Healthcare standing out as cheap medical stocks.

zacks.com - 2026-07-09 15:26:04

Analysts Estimate Elevance Health (ELV) to Report a Decline in Earnings: What to Look Out for

Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-08 11:01:10

Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-39.

businesswire.com - 2026-07-06 16:30:00

Can Elevance Recover $115 Million Through Its CMS Lawsuit?

ELV seeks to recover an estimated $115 million through a CMS lawsuit over Medicare Advantage Star Ratings and disputed bonus payments.

zacks.com - 2026-07-03 11:15:27

Can Carelon Drive Elevance Health's Future Earnings Growth?

Carelon is becoming a major growth driver for ELV, boosting revenues, care efficiency and long-term earnings potential despite near-term investment pressure.

zacks.com - 2026-06-26 12:46:27

New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act

INDIANAPOLIS--(BUSINESS WIRE)--The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop.

businesswire.com - 2026-06-25 09:00:00

Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation

INDIANAPOLIS--(BUSINESS WIRE)--Thomas Carr Howe Middle School today celebrated the unveiling of a newly transformed fitness and strength training space made possible through a partnership with Elevance Health and the Impact Fitness Foundation (IFF). The project marks the fifth consecutive year that Elevance Health and IFF have invested in Indianapolis schools through community fitness initiatives connected to the Elevance Health Women's Fort Myers Tipoff, a premier collegiate basketball tournam.

businesswire.com - 2026-06-24 15:00:00

ELV Accelerates Clinical Reviews Through Health OS Platform

Elevance Health's Health OS is cutting review delays and admin work, with early results showing fewer denials and holds as digital healthcare adoption expands.

zacks.com - 2026-06-24 12:42:06

Elevance Health (ELV) Upgraded to Buy: Here's What You Should Know

Elevance Health (ELV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-06-23 13:01:14

Elevance Health Makes Clinical Review Faster, More Connected with Health OS

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health today announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers and members through Health OS. Health OS is Elevance Health's secure data platform designed to connect health information across electronic health records (EHRs), labs, and health information exchanges, helping support more informed and timely clinical decisions while reducing administrative burden f.

businesswire.com - 2026-06-23 08:15:00

Elevance Tops $1B in Housing Investments: What's Driving the Strategy?

ELV surpasses $1B in affordable housing investments, aiming to improve health outcomes, expand care access and support long-term growth.

zacks.com - 2026-06-18 13:46:07

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced it has invested $640 million in affordable housing over the past five years, building on more than $1 billion invested over nearly two decades. These investments reflect the company's continued commitment to addressing social drivers of health, helping lower the total cost of care, and expanding access to safe, stable, and affordable housing.Over the past five years, Elevance Health has invested $640 million across 15 pro.

businesswire.com - 2026-06-17 10:00:00

Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide

Elevance Health (NYSE: ELV) today announced it has invested $640 million in affordable housing over the past five years, building on more than $1 billion invest

gurufocus.com - 2026-06-17 10:00:00

ELV DCF Analysis: Intrinsic Value $643 vs Price $402

On June 16, 2026, we present a discounted cash flow (DCF) analysis for Elevance Health Inc (ELV). The stock has shown a price performance of -3.5% over the past

gurufocus.com - 2026-06-16 07:27:00

Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?

Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.

fool.com - 2026-06-15 16:42:41

Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized Support

INDIANAPOLIS--(BUSINESS WIRE)--Across the country, three in four adults are living with at least one chronic condition. Elevance Health is helping people manage chronic conditions by creating more personalized, connected experiences that make it easier to understand care, stay on track, and know what to do next. Elevance Health is working to simplify that experience by using data, digital tools, and proactive outreach to connect the people it serves to the support they need when they need it, t.

businesswire.com - 2026-06-15 10:00:00

Elevance Health, Inc. (ELV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Elevance Health, Inc. (ELV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-11 08:22:09

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

seekingalpha.com - 2026-06-05 18:19:56

Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)

Elevance Health, Inc. has rebounded ~34% from its March lows, supported by sector recovery and improved Q1 2026 results. Q1 2026 saw ELV revenue up 1.5% to $49.5bn, adjusted EPS up 5.1% to $12.58, and a benefit expense ratio improvement to 86.8%. ELV raised 2026 adjusted EPS guidance to at least $26.75 and expects a return to 12% adjusted EPS growth in 2027.

seekingalpha.com - 2026-06-01 09:35:33

Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health is advancing its commitment to improving healthcare access by addressing one of healthcare's most pressing challenges: the digital divide. Through innovative programs like Get Connected for Health and services offered by CareBridge, a subsidiary of Elevance Health, the company is helping ensure that individuals - especially those in underserved communities - have the tools, connectivity, and support needed to help them better manage their healthcar.

businesswire.com - 2026-05-27 06:46:00

Elevance Health (ELV) Up 12.6% Since Last Earnings Report: Can It Continue?

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-05-22 12:32:34

AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers

Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution.

247wallst.com - 2026-05-19 09:25:13

Is ELV Undervalued? DCF Says Worth $643

On May 19, 2026, we present a detailed DCF analysis for Elevance Health Inc (ELV), a company currently trading at $394.07. The stock has shown a strong price pe

gurufocus.com - 2026-05-19 07:49:00

Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript

Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com - 2026-05-13 09:50:47

A Look at Elevance Health Inc (ELV) After 4.0% Gain -- GF Value $518.29 vs Price $393.30

On May 12, 2026, Elevance Health Inc (ELV) shares rose 4.0% today, bringing the current price to $393.30. The stock has experienced a 52-week range between $273

gurufocus.com - 2026-05-12 19:01:00

Is ELV Undervalued? DCF Says Worth $643

On May 12, 2026, we present a DCF analysis for Elevance Health Inc (ELV), a company currently trading at $381.75. The stock has shown mixed performance, with a

gurufocus.com - 2026-05-12 08:20:00

Is ELV Undervalued? DCF Says Worth $643

On May 08, 2026, we conducted a DCF analysis for Elevance Health Inc (ELV) to assess its intrinsic value in the context of its recent price performance. Over th

gurufocus.com - 2026-05-08 08:24:00

Major health insurers show signs of recovery – but a key test looms

Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But analysts caution that insurers have incomplete data on medical costs in the first quarter due to a lag in claims processing, which sets up the second quarter as the real proving ground.

cnbc.com - 2026-05-05 07:00:01

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Don Lair writes about options income, dividend strategy, and the kind of boring-but-durable investing that actually funds retirement.

247wallst.com - 2026-05-04 14:11:51

Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care

INDIANAPOLIS--(BUSINESS WIRE)--Despite growing awareness, mental health concerns remain difficult to navigate and often lead to avoidable crises, costly emergency room visits, and long-term strain on individuals, families, and an already overburdened healthcare system. With nearly one in five Americans experiencing a diagnosable mental health condition each year, the need for funding and systemic improvement has never been greater. That's why Elevance Health is focused on addressing some of the.

businesswire.com - 2026-05-04 14:10:00

Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider Recognition Program. The program spotlights the top one percent of primary care providers in Elevance Health's nationwide affiliated health plan network of about 7,200 value-based care and evaluated provider partners. The recognition highlights primary care providers who exhibit excellence in deliv.

businesswire.com - 2026-05-01 08:00:00

Elevance Health's Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses

INDIANAPOLIS--(BUSINESS WIRE)--As small businesses continue to face rising healthcare costs, Elevance Health's affiliated health plans are delivering solutions that help employers offer competitive benefits, improve health outcomes, and keep costs more affordable and more predictable. Recent research shows small businesses and their employees have experienced healthcare cost increases of 26% over the past five years, underscoring the need for more stable and predictable solutions. Small busines.

businesswire.com - 2026-04-30 08:00:00

Comerica Bank Sells 2,331 Shares of Elevance Health, Inc. $ELV

Comerica Bank lessened its holdings in Elevance Health, Inc. (NYSE: ELV) by 6.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,056 shares of the company's stock after selling 2,331 shares during the period. Comerica Bank's holdings

defenseworld.net - 2026-04-29 14:41:34

Get ELV Insider Trade Alerts

ELV Price Target Summary

Last Month

$467.60

5 analysts

Last Quarter

$436.65

17 analysts

Last Year

$408.15

46 analysts

All Time

$472.79

91 analysts

ELV Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-14 Truist Securities Maintain Buy Buy
2026-07-14 TD Cowen Maintain Buy Buy
2026-07-13 Wells Fargo Maintain Overweight Overweight
2026-07-09 RBC Capital Maintain Sector Perform Sector Perform
2026-07-07 Cantor Fitzgerald Maintain Overweight Overweight
2026-07-02 Bernstein Maintain Outperform Outperform
2026-06-08 Mizuho Maintain Outperform Outperform
2026-06-08 JP Morgan Maintain Overweight Overweight
2026-06-04 B of A Securities Maintain Buy Buy
2026-06-04 Morgan Stanley Maintain Equal Weight Equal Weight
2026-06-01 Truist Securities Maintain Buy Buy
2026-05-26 Barclays Maintain Overweight Overweight
2026-05-22 UBS Maintain Buy Buy
2026-05-20 Mizuho Maintain Outperform Outperform
2026-05-20 Deutsche Bank Upgrade Hold Buy
2026-04-29 B of A Securities Upgrade Neutral Buy
2026-04-28 JP Morgan Maintain Overweight Overweight
2026-04-24 Bernstein Maintain Outperform Outperform
2026-04-24 Barclays Maintain Overweight Overweight
2026-04-24 Guggenheim Maintain Buy Buy
2026-04-23 Evercore ISI Group Maintain In Line In Line
2026-04-23 Baird Maintain Neutral Neutral
2026-04-20 Jefferies Maintain Buy Buy
2026-04-13 Truist Securities Maintain Buy Buy
2026-03-11 Mizuho Maintain Outperform Outperform
2026-02-02 Bernstein Maintain Outperform Outperform
2026-02-02 JP Morgan Maintain Overweight Overweight
2026-02-02 Truist Securities Maintain Buy Buy
2026-01-30 Barclays Maintain Overweight Overweight
2026-01-30 Wells Fargo Maintain Overweight Overweight
2026-01-29 Guggenheim Maintain Buy Buy
2026-01-22 Guggenheim Maintain Buy Buy
2026-01-08 Wolfe Research Upgrade Peer Perform Outperform
2026-01-07 Wells Fargo Maintain Overweight Overweight
2026-01-05 Barclays Maintain Overweight Overweight
2025-12-19 Deutsche Bank Downgrade Buy Hold
2025-12-18 Morgan Stanley Maintain Equal Weight Equal Weight
2025-11-26 TD Cowen Maintain Buy Buy
2025-11-04 Mizuho Maintain Outperform Outperform
2025-10-28 JP Morgan Maintain Overweight Overweight
2025-10-23 TD Cowen Maintain Buy Buy
2025-10-22 Barclays Maintain Overweight Overweight
2025-10-22 Wells Fargo Maintain Overweight Overweight
2025-10-14 Morgan Stanley Maintain Equal Weight Equal Weight
2025-10-10 B of A Securities Maintain Neutral Neutral
2025-10-09 Mizuho Maintain Outperform Outperform
2025-10-09 Barclays Maintain Overweight Overweight
2025-10-08 Guggenheim Maintain Buy Buy
2025-10-07 Wells Fargo Maintain Overweight Overweight
2025-09-05 UBS Maintain Buy Buy
2025-09-04 Barclays Maintain Overweight Overweight
2025-08-15 Wells Fargo Maintain Overweight Overweight
2025-07-25 Baird Maintain Neutral Neutral
2025-07-22 JP Morgan Maintain Overweight Overweight
2025-07-22 Barclays Maintain Overweight Overweight
2025-07-21 Argus Research Downgrade Buy Hold
2025-07-18 Guggenheim Maintain Buy Buy
2025-07-18 Barclays Maintain Overweight Overweight
2025-07-18 Morgan Stanley Maintain Overweight Overweight
2025-07-18 Leerink Partners Downgrade Outperform Market Perform
2025-07-18 UBS Maintain Buy Buy
2025-07-16 Truist Securities Maintain Buy Buy
2025-07-15 Wells Fargo Maintain Overweight Overweight
2025-07-14 UBS Maintain Buy Buy
2025-07-09 Barclays Maintain Overweight Overweight
2025-06-09 Truist Securities Maintain Buy Buy
2025-06-04 RBC Capital Maintain Outperform Outperform
2025-06-02 Barclays Maintain Overweight Overweight
2025-04-25 Argus Research Maintain Buy Buy
2025-04-23 Barclays Maintain Overweight Overweight
2025-04-23 Guggenheim Maintain Buy Buy
2025-04-23 Cantor Fitzgerald Maintain Overweight Overweight
2025-04-23 RBC Capital Maintain Outperform Outperform
2025-04-15 Baird Downgrade Outperform Neutral
2025-04-11 Truist Securities Maintain Buy Buy
2025-04-09 Mizuho Maintain Outperform Outperform
2025-03-17 Argus Research Upgrade Hold Buy
2025-01-29 Argus Research Maintain Hold Hold
2025-01-28 Wells Fargo Maintain Overweight Overweight
2025-01-24 Barclays Maintain Overweight Overweight
2025-01-24 Cantor Fitzgerald Maintain Overweight Overweight
2025-01-06 Truist Securities Maintain Buy Buy
2024-11-05 Mizuho Maintain Outperform Outperform
2024-11-04 Wells Fargo Maintain Overweight Overweight
2024-10-23 Morgan Stanley Maintain Overweight Overweight
2024-10-22 Barclays Maintain Overweight Overweight
2024-10-21 TD Cowen Maintain Buy Buy
2024-10-18 Argus Research Downgrade Buy Hold
2024-10-18 RBC Capital Maintain Outperform Outperform
2024-10-18 UBS Maintain Buy Buy
2024-10-18 Truist Securities Maintain Buy Buy
2024-10-18 Cantor Fitzgerald Maintain Overweight Overweight
2024-10-10 Barclays Maintain Overweight Overweight
2024-10-01 Cantor Fitzgerald Maintain Overweight Overweight
2024-09-20 Cantor Fitzgerald Maintain Overweight Overweight
2024-09-10 Cantor Fitzgerald Maintain Overweight Overweight
2024-09-05 Stephens & Co. Maintain Overweight Overweight
2024-08-19 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-23 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-22 Wells Fargo Maintain Overweight Overweight
2024-07-19 TD Cowen Maintain Buy Buy
2024-07-18 B of A Securities Downgrade Buy Neutral
2024-07-18 Barclays Maintain Overweight Overweight
2024-07-18 RBC Capital Maintain Outperform Outperform
2024-07-15 Truist Securities Maintain Buy Buy
2024-07-10 Cantor Fitzgerald Maintain Overweight Overweight
2024-06-12 Cantor Fitzgerald Maintain Overweight Overweight
2024-06-11 Stephens & Co. Maintain Overweight Overweight
2024-06-04 B of A Securities Maintain Buy Buy
2024-05-30 JP Morgan Maintain Overweight Overweight
2024-04-24 Mizuho Maintain Buy Buy
2024-04-19 UBS Maintain Buy Buy
2024-04-19 Jefferies Maintain Buy Buy
2024-04-19 Wells Fargo Maintain Overweight Overweight
2024-04-19 RBC Capital Maintain Outperform Outperform
2024-04-19 Truist Securities Maintain Buy Buy
2024-04-19 Barclays Maintain Overweight Overweight
2024-04-10 Cantor Fitzgerald Maintain Overweight Overweight
2024-04-08 Wells Fargo Maintain Overweight Overweight
2024-04-04 Cantor Fitzgerald Maintain Overweight Overweight
2024-02-14 Cantor Fitzgerald Maintain Overweight Overweight
2024-02-02 Cantor Fitzgerald Maintain Overweight Overweight
2024-01-25 RBC Capital Maintain Outperform Outperform
2024-01-25 Cantor Fitzgerald Maintain Overweight Overweight
2024-01-19 Cantor Fitzgerald Maintain Overweight Overweight
2023-11-21 Cantor Fitzgerald Maintain Overweight Overweight
2023-11-17 JP Morgan Maintain Overweight Overweight
2023-10-19 Cantor Fitzgerald Maintain Overweight Overweight
2023-10-19 Morgan Stanley Maintain Overweight Overweight
2023-09-14 Cantor Fitzgerald Maintain Overweight Overweight
2023-07-25 Morgan Stanley Maintain Overweight Overweight
2023-07-24 TD Cowen Maintain Outperform Outperform
2023-07-20 Stephens & Co. Maintain Overweight Overweight
2023-07-20 RBC Capital Maintain Outperform Outperform
2023-07-13 UBS Maintain Buy Buy
2023-07-12 Wolfe Research Downgrade Outperform Peer Perform
2023-07-07 JP Morgan Maintain Overweight Overweight
2023-06-20 Truist Securities Maintain Buy Buy
2023-04-27 Morgan Stanley Upgrade Equal Weight Overweight
2023-04-24 Wells Fargo Maintain Overweight Overweight
2023-04-21 Loop Capital Maintain Buy Buy
2023-04-21 Cantor Fitzgerald Maintain Overweight Overweight
2023-04-20 TD Cowen Maintain Outperform Outperform
2023-03-28 RBC Capital Upgrade Sector Perform Outperform
2023-03-24 Truist Securities Maintain Buy Buy
2023-03-21 Wells Fargo Maintain Equal Weight Equal Weight
2023-03-08 Deutsche Bank Maintain Buy Buy
2023-02-23 JP Morgan Maintain Overweight Overweight
2023-01-26 SVB Leerink Maintain Outperform Outperform
2023-01-26 RBC Capital Maintain Sector Perform Sector Perform
2023-01-04 Wells Fargo Maintain Overweight Overweight
2022-11-10 Mizuho Maintain Buy Buy
2022-10-21 Morgan Stanley Maintain Equal Weight Equal Weight
2022-10-21 Deutsche Bank Maintain Buy Buy
2022-09-09 B of A Securities Upgrade Neutral Buy
2022-08-22 SVB Leerink Upgrade Market Perform Outperform
2022-07-28 Wells Fargo Maintain Overweight Overweight
2022-07-25 Morgan Stanley Maintain Equal Weight Equal Weight
2022-07-22 SVB Leerink Maintain Market Perform Market Perform
2022-06-21 Morgan Stanley Downgrade Overweight Equal Weight
2022-06-17 Loop Capital Maintain Buy Buy
2022-05-25 Wells Fargo Maintain Overweight Overweight
2022-04-25 BMO Capital Maintain Outperform Outperform
2022-04-22 Deutsche Bank Maintain Buy Buy
2022-04-21 Morgan Stanley Maintain Overweight Overweight
2022-04-21 SVB Leerink Maintain Market Perform Market Perform
2022-04-21 Credit Suisse Maintain Outperform Outperform
2022-04-21 Goldman Sachs Maintain Buy Buy
2022-03-29 UBS Maintain Buy Buy
2022-03-15 SVB Leerink Maintain Market Perform Market Perform
2022-02-07 Argus Research Maintain Buy Buy
2022-01-28 Morgan Stanley Maintain Overweight Overweight
2022-01-27 SVB Leerink Maintain Market Perform Market Perform
2021-12-20 Mizuho Upgrade Neutral Buy
2021-12-17 Morgan Stanley Maintain Overweight Overweight
2021-10-29 Mizuho Maintain Neutral Neutral
2021-10-25 Wells Fargo Maintain Overweight Overweight
2021-10-21 Stephens & Co. Maintain Overweight Overweight
2021-10-21 Morgan Stanley Maintain Overweight Overweight
2021-10-21 Credit Suisse Maintain Outperform Outperform
2021-10-21 SVB Leerink Maintain Market Perform Market Perform
2021-10-21 RBC Capital Maintain Sector Perform Sector Perform
2021-10-21 Barclays Maintain Overweight Overweight
2021-08-31 Morgan Stanley Maintain Overweight Overweight
2021-07-22 Jefferies Maintain Buy Buy
2021-07-22 Barclays Maintain Overweight Overweight
2021-07-22 RBC Capital Maintain Sector Perform Sector Perform
2021-07-22 Stephens & Co. Maintain Overweight Overweight
2021-07-22 Mizuho Maintain Neutral Neutral
2021-07-22 BMO Capital Maintain Outperform Outperform
2021-07-02 Morgan Stanley Maintain Overweight Overweight
2021-06-10 RBC Capital Downgrade Outperform Sector Perform
2021-05-03 Mizuho Maintain Neutral Neutral
2021-04-22 Credit Suisse Maintain Outperform Outperform
2021-04-22 Barclays Maintain Overweight Overweight
2021-04-22 Stephens & Co. Maintain Overweight Overweight
2021-04-22 RBC Capital Maintain Outperform Outperform
2021-04-14 Truist Securities Maintain Buy Buy
2021-04-14 Cowen & Co. Maintain Outperform Outperform
2021-03-04 Truist Securities Upgrade Hold Buy
2021-01-28 Credit Suisse Maintain Outperform Outperform
2021-01-26 Cowen & Co. Maintain Outperform Outperform
2021-01-15 Jefferies Upgrade Hold Buy
2020-12-14 SVB Leerink Maintain Outperform Outperform
2020-10-29 Deutsche Bank Maintain Buy Buy
2020-10-29 SVB Leerink Maintain Outperform Outperform
2020-07-30 Deutsche Bank Maintain Buy Buy
2020-07-30 RBC Capital Maintain Outperform Outperform
2020-07-30 SVB Leerink Maintain Outperform Outperform
2020-07-10 Jefferies Maintain Hold Hold
2020-05-21 SunTrust Robinson Humphrey Maintain Hold Hold
2020-05-12 UBS Maintain Buy Buy
2020-04-30 Morgan Stanley Maintain Overweight Overweight
2020-04-29 CFRA Upgrade Hold Buy
2020-04-13 Morgan Stanley Maintain Overweight Overweight
2020-04-13 SunTrust Robinson Humphrey Maintain Hold Hold
2020-04-09 Jefferies Downgrade Buy Hold
2020-03-27 Morgan Stanley Maintain Overweight Overweight
2020-02-18 Deutsche Bank Maintain Buy Buy
2020-01-31 Credit Suisse Maintain Outperform Outperform
2020-01-31 Morgan Stanley Maintain Overweight Overweight
2020-01-31 Deutsche Bank Maintain Buy Buy
2020-01-30 B of A Securities Maintain Neutral Neutral
2020-01-29 Stephens & Co. Maintain Overweight Overweight
2019-12-20 JP Morgan Maintain Overweight Overweight
2019-12-06 Bank of America Downgrade Buy Neutral
2019-11-22 Morgan Stanley Maintain Overweight Overweight
2019-11-18 SunTrust Robinson Humphrey Maintain Hold Hold
2019-10-24 Morgan Stanley Maintain Overweight Overweight
2019-10-24 Credit Suisse Maintain Outperform Outperform
2019-09-26 Morgan Stanley Maintain Overweight Overweight
2019-07-12 Morgan Stanley Maintain Overweight Overweight
2019-04-25 Barclays Maintain Overweight Overweight
2019-04-25 Morgan Stanley Maintain Overweight Overweight
2019-04-17 Barclays Maintain Overweight Overweight
2019-03-08 Credit Suisse Maintain Outperform Outperform
2019-01-31 Morgan Stanley Maintain Overweight Overweight
2019-01-03 Evercore ISI Group Upgrade In Line Outperform
2018-12-04 Cantor Fitzgerald Maintain Overweight Overweight
2018-12-03 Jefferies Maintain Buy Buy
2018-11-06 Citigroup Maintain Neutral Neutral
2018-11-01 BMO Capital Maintain Outperform Outperform
2018-11-01 Credit Suisse Maintain Outperform Outperform
2018-11-01 Barclays Maintain Overweight Overweight
2018-09-10 Citigroup Downgrade Buy Neutral
2018-09-05 Morgan Stanley Upgrade Equal Weight Overweight
2018-07-26 Morgan Stanley Maintain Equal Weight Equal Weight
2018-07-09 BMO Capital Upgrade Market Perform Outperform
2018-04-26 JP Morgan Upgrade Neutral Overweight
2018-04-26 Morgan Stanley Maintain Equal Weight Equal Weight
2018-04-26 Credit Suisse Maintain Outperform Outperform
2018-02-01 Morgan Stanley Maintain Equal Weight Equal Weight
2018-02-01 Wells Fargo Maintain Outperform Outperform
2018-01-12 Jefferies Upgrade Hold Buy
2018-01-03 PiperJaffray Upgrade Neutral Overweight
2017-11-17 Bank of America Maintain Buy Buy
2017-11-07 Leerink Swann Maintain Outperform Outperform
2017-10-26 Morgan Stanley Maintain Equal Weight Equal Weight
2017-10-13 Jefferies Maintain Hold Hold
2017-08-17 Morgan Stanley Maintain Equal Weight Equal Weight
2017-07-14 Bank of America Maintain Buy Buy
2017-07-13 Deutsche Bank Maintain Hold Hold
2017-07-12 Credit Suisse Maintain Neutral Neutral
2017-04-27 Cantor Fitzgerald Upgrade Hold Overweight
2017-01-04 Stifel Nicolaus Downgrade Buy Hold
2016-11-22 Wolfe Research Upgrade Peer Perform Outperform
2016-11-15 Wells Fargo Upgrade Market Perform Outperform
2016-10-17 JP Morgan Downgrade Overweight Neutral
2016-09-13 Jefferies Downgrade Buy Hold
2016-07-28 Citigroup Maintain Buy Buy
2016-07-28 Jefferies Maintain Buy Buy
2016-07-28 Barclays Maintain Equal Weight Equal Weight
2016-04-04 Leerink Swann Maintain Outperform Outperform
2016-01-28 Jefferies Maintain Buy Buy
2016-01-28 FBR Capital Maintain Market Perform Market Perform
2016-01-20 Goldman Sachs Upgrade Neutral Buy
2016-01-08 Jefferies Maintain Buy Buy
2015-10-29 Barclays Maintain Equal Weight Equal Weight
2015-07-30 Cantor Fitzgerald Maintain Hold Hold
2015-07-27 Sterne Agee CRT Upgrade Neutral Buy
2015-06-17 Morgan Stanley Maintain Equal Weight Equal Weight
2015-06-15 Cowen & Co. Maintain Outperform Outperform
2015-05-22 Susquehanna Maintain Positive Positive
2015-05-01 Oppenheimer Maintain Outperform Outperform
2015-04-30 Barclays Maintain Equal Weight Equal Weight
2015-04-29 Jefferies Maintain Buy Buy
2015-04-16 Oppenheimer Maintain Outperform Outperform
2015-03-20 Barclays Maintain Equal Weight Equal Weight
2015-01-29 Jefferies Maintain Buy Buy
2015-01-28 Credit Suisse Maintain Neutral Neutral
2015-01-20 Jefferies Maintain Buy Buy
2015-01-08 Barclays Maintain Equal Weight Equal Weight
2015-01-06 Deutsche Bank Upgrade Hold Buy